Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on January 25, 2007
Japanese Journal of Clinical Oncology 2007 37(2):140-145; doi:10.1093/jjco/hyl136
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/2/140    most recent
hyl136v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ueda, Y.
Right arrow Articles by Yamagishi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ueda, Y.
Right arrow Articles by Yamagishi, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Induction of Peptide-Specific Immune Response in Patients with Primary Malignant Melanoma of the Esophagus after Immunotherapy Using Dendritic Cells Pulsed with MAGE Peptides

Yuji Ueda, Keiji Shimizu, Tsuyoshi Itoh, Nobuaki Fuji, Kei Naito, Atsushi Shiozaki, Yoshiki Yamamoto, Takeshi Shimizu, Arihiro Iwamoto, Hidemasa Tamai and Hisakazu Yamagishi

Department of Surgery and Oncology of Digestive System, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

For reprints and all correspondence: Yuji Ueda, Department of Surgery, Division of Digestive Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji Kamigyo-ku, Kyoto 602-8566, Japan. E-mail: yueda{at}koto.kpu-m.ac.jp

Received June 17, 2006; accepted August 25, 2006

Primary malignant melanoma of the esophagus (PMME) is a very rare disease with an extremely poor prognosis. Surgery is currently considered its best treatment, while any other measures are ineffective. We studied the effect of active specific immunotherapy using monocyte-derived dendritic cells (DCs) pulsed with the epitope peptides of melanoma-associated antigens (MAGE-1, MAGE-3) in patients with PMME after surgery, for the first time. The patient received passive immunotherapy with lymphokine-activated killer cells concomitantly. Two HLA-A24-positive patients with PMME were treated. Both patients initially received radical esophagectomy with regional lymphadenectomy, followed by adjuvant chemotherapy with dacarbazine, nimustine, vincristine and interferon-{alpha}. In the case 1 patient, active specific immunotherapy was used to treat a large abdominal lymph node metastasis that became obvious 21 months after surgery. The disease remained stable for 5 months, and the patient survived for 12 months after the initiation of immunotherapy. In the case 2 patient, immunotherapy was tried as post-operative adjuvant treatment after adjuvant chemotherapy. There was no tumor recurrence for 16 months after the immunotherapy. As of 49 months after esophagectomy, the patient is still alive. In both patients, the ability of peripheral lymphocytes to produce IFN-{gamma} in vitro in response to peptide stimulation was significantly enhanced and delayed-type hypersensitivity skin test response to MAGE-3 peptide was turned positive after immunotherapy. In conclusion, active specific immunotherapy for PMME with the use of DCs and MAGE peptides was safe and capable of inducing peptide-specific immune responses. This case report warrants further clinical evaluation of this immunotherapy for PMME.

Key Words: esophageal malignant melanoma • cellular immunotherapy • dendritic cell • lymphokine-activated killer cell • MAGE peptide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
Y. AKIYAMA, K. MARUYAMA, S. TAI, M. KOMIYAMA, A. IIZUKA, M. TAKIKAWA, C. OHSHITA, A. YAMAMOTO, N. YAMAZAKI, Y. KIYOHARA, et al.
Characterization of a MAGE-1-derived HLA-A24 Epitope-specific CTL Line from a Japanese Metastatic Melanoma Patient
Anticancer Res, February 1, 2009; 29(2): 647 - 655.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.